

Growing up with your airway microbiota: a risky business

Bushra Ahmed,¹ Michael J Cox,² Leah Cuthbertson²

Childhood is a critical time for respiratory health, with environmental and infectious exposures being linked to future respiratory disease and susceptibility.^{1,2} Respiratory microbiome research has introduced a new context for these exposures due to the presence of a pre-existing microbial community in both the upper and lower respiratory tract in healthy children.³⁻⁵ Variation in community composition has been observed in chronic lung diseases,^{6,7} and particular micro-organisms or combinations of organisms in infants have been associated with future disease development. Thus deviation from a healthy microbiota in early life appears to play an important role in disease development, with changes evident by 1 week of age.⁸ The dynamics of the infant airway microbiota and its relationship to disease development has therefore been the focus of increasing attention.

Acute respiratory infections (ARIs) are common in children under 5 years of age,⁹ and indications suggest that susceptibility might be, at least partly, determined by the microbiota.^{5,8} Toivonen and colleagues¹⁰ have conducted the largest study of the respiratory microbiome in infants to date, obtaining a nasal swab at 2 months of age from 839 infants and parent-recorded data on respiratory infections until 24 months of age to look at the incidence of ARI.

The study was conducted, described and controlled, taking into account many of the methodological issues that can arise when using the 16S rRNA gene sequencing approach for the microbiota.¹¹

There are clear and reproducible differences between sampling types and areas of the respiratory tract. Choices have to be made during study design as to the method and area most appropriate for the question and, pragmatically, one that can be obtained at scale.^{12,13} In Toivonen and colleagues¹⁰ Finnish cohort, nasal swabs were collected. Nasal swabs can be expected to represent the upper

respiratory tract nasal microbiota and infections that start or are restricted to the nasopharynx. Although the relationship with the lower respiratory tract may be less well represented, the necessary sampling for this would likely be prohibitive in a cohort of this size.

The authors stratified the infants according to their nasal microbiota, with each of the five resulting groups represented by a particular dominant organism. Of these the highest reported incidence rate of respiratory infections was in the *Moraxella*-dominant group and the lowest rate in the *Corynebacteriaceae* group. These results echo that of previous, smaller longitudinal studies of the nasopharyngeal microbiota in infancy and add further evidence of a potentially pathogenic role of *Moraxella* and a protective role of *Corynebacterium* in the risk of developing ARIs.⁸ *Moraxella* has also been associated with respiratory disease in a range of different contexts, such as asthma¹ and COPD.¹⁴ It should be noted that although rigorous statistical methods have been applied, there is quite a large difference in the number of infants in each of these groups, and a future study might corroborate these findings by targeted recruitment of equal numbers of study participants in each organism-dominated group and recording ARI incidence. The lack of a *Haemophilus*-dominated microbiota group is surprising as this was identified in a previous infant cohort as a risk for ARIs,⁵ and *Haemophilus* is an organism associated with chronic lung diseases in childhood such as asthma¹ and primary ciliary dyskinesia.¹⁵ This could be a feature of this cohort or might represent methodological differences and is worthy of additional exploration.

As Toivonen *et al*¹⁰ correctly state, association does not prove causality. In this study a higher rate of respiratory viral detection was observed in the *Moraxella*-dominated group. Viral infections are recognised as a common cause of ARIs in infancy. The authors of this study were unfortunately unable to assess the inflammatory effects of different microbiota profiles. Although viral infections were adjusted for in their analyses, the interactions between viruses, the microbiota and host inflammation were not explored. In

vitro work looking at interactions within and between microbes and the host may help us to better understand the causal mechanisms for these differences and determine therapeutic targets for promotion of lung health.

As the authors continue to follow up these children longitudinally, it will be interesting to observe the impact of different microbiota profiles on later respiratory health and whether the children sampled stay within the same groups. Recurrent ARIs in the first year of life have been shown to be a significant risk factor for both reduced lung function at 1 year of age and hospitalisations with respiratory symptoms, particularly asthma, at 3 years of age in two large population-based studies in children in South Africa¹⁶ and Australia, respectively.¹⁷ Surprisingly, Toivonen *et al*¹⁰ did not find an association with microbiota profiles and recurrent wheezing, although this may reflect the low incidence of recurrent wheezing in this cohort, and the long-term implications of this study on future lung health remain unknown. Nonetheless, there is a growing body of evidence that interventions to reduce the severity and frequency of ARIs in infancy could improve lung health.

What such interventions should entail, however, is debatable. Given the pathogenic role of *Moraxella* in promoting neutrophilic airway inflammation¹⁸ and disease susceptibility, an argument could be made for aggressive antibiotic treatment for *Moraxella*-dominated communities. In an era of increasing antimicrobial resistance, caution should be taken when advocating such an approach in the absence of evidence of causation between *Moraxella* and lung disease. The current study reported greater use of systemic antibiotics in the *Moraxella*-dominated and *Streptococcus*-dominated groups before 2 months of age. It is unknown if the need for early antibiotic treatment is a result of or a risk factor for the development of a *Moraxella*-dominated community. As such, further longitudinal investigation into the development of the microbial community in early life is required.

The microbiota throughout the body has consistently been shown to be highly individual.¹⁹ Personalised treatments based on risk stratification by the dominant organism in the microbiota, similar to that used in this study, may prove beneficial. Such strategies have yet to be evaluated in paediatric cohorts in whom the greatest window of opportunity exists to prevent aberrant development of the

¹Department of Respiratory Paediatrics, Royal Brompton and Harefield NHS Foundation Trust, London, UK

²National Heart and Lung Institute, Imperial College of Science Technology and Medicine, London, UK

Correspondence to Dr Michael J Cox, National Heart and Lung Institute, Imperial College of Science Technology and Medicine, London SW3 6LY, UK; michael.cox1@imperial.ac.uk

microbiota and influence long-term respiratory health.

The insights afforded by this large, well-conducted study by Toivonen *et al*¹⁰ provide growing evidence that some microbiota profiles, potentially those dominated by *Moraxella*, may be related to an increased risk of future lung disease. Future work in this area exploring mechanisms of causation and longitudinal outcomes will help to determine if these microbiota profiles in infancy are truly risky or innocent bystanders in children with increased risk of ARIs.

Contributors The authors contributed equally to this editorial.

Funding MJC and LC were supported by a Wellcome Trust Joint Senior Investigator Award to Professor Miriam Moffatt and Professor William Cookson.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Ahmed B, Cox MJ, Cuthbertson L. *Thorax* 2019;**74**:525–526.

Accepted 25 March 2019
Published Online First 9 May 2019



► <http://dx.doi.org/10.1136/thoraxjnl-2018-212629>

Thorax 2019;**74**:525–526.
doi:10.1136/thoraxjnl-2019-213162

REFERENCES

1. Bisgaard H, Hermansen MN, Buchvald F, *et al*. Childhood asthma after bacterial colonization of the airway in neonates. *N Engl J Med Overseas Ed* 2007;**357**:1487–95.
2. Ege MJ, Mayer M, Normand A-C, *et al*. Exposure to environmental microorganisms and childhood asthma. *New England Journal of Medicine* 2011;**364**:701–9.
3. Hilty M, Burke C, Pedro H, *et al*. Disordered microbial communities in asthmatic airways. *PLoS ONE* 2010;**5**:e8578.
4. Mika M, Mack I, Korten I, *et al*. Dynamics of the nasal microbiota in infancy: a prospective cohort study. *J Allergy Clin Immunol* 2015;**135**:e911:905–12.
5. Biesbroek G, Tsvitvadze E, Sanders EAM, *et al*. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. *Am J Respir Crit Care Med* 2014;**190**:1283–92.
6. Mika M, Korten I, Qi W, *et al*. The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study. *Lancet Respir Med* 2016;**4**:627–35.
7. Teo SM, Mok D, Pham K, *et al*. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;**17**:704–15.
8. Bosch AATM, de Steenhuijsen Piter WAA, van Houten MA, *et al*. Maturation of the infant respiratory microbiota, environmental drivers, and health consequences. A prospective cohort study. *Am J Respir Crit Care Med* 2017;**196**:1582–90.
9. Goto T, Tsugawa Y, Mansbach JM, *et al*. Trends in infectious disease hospitalizations in US children, 2000 to 2012. *Pediatr Infect Dis J* 2016;**35**:e158–63.
10. Toivonen L, Hasegawa K, Waris M, *et al*. Early nasal microbiota and acute respiratory infections during the first years of life. *Thorax* 2019;**74**:593–600.
11. Salter SJ, Cox MJ, Turek EM, *et al*. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. *BMC Biol* 2014;**12**.
12. Charlson ES, Bittinger K, Haas AR, *et al*. Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med* 2011;**184**:957–63.
13. Marsh RL, Kaestli M, Chang AB, *et al*. The microbiota in bronchoalveolar lavage from young children with chronic lung disease includes taxa present in both the oropharynx and nasopharynx. *Microbiome* 2016;**4**.
14. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med* 2008;**359**:2355–65.
15. Alanin MC, Nielsen KG, von Buchwald C, *et al*. A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. *Clinical Microbiology and Infection* 2015;**21**:1093.e1–1093.e7.
16. Gray DM, Turkovic L, Willemsse L, *et al*. Lung function in African infants in the Drakenstein child health study. Impact of lower respiratory tract illness. *Am J Respir Crit Care Med* 2017;**195**:212–20.
17. Moore HC, Hall GL, de Klerk N. Infant respiratory infections and later respiratory hospitalisation in childhood. *Eur Respir J* 2015;**46**:1334–41.
18. Robinson PFM, Pattaroni C, Cook J, *et al*. Lower airway microbiota associates with inflammatory phenotype in severe preschool wheeze. *J Allergy Clin Immunol* 2018.
19. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012;**486**:207–14.